Upgrade to Pro — share decks privately, control downloads, hide ads and more …

John Ashton

Lung Foundation NZ
November 11, 2015
87

John Ashton

Lung Foundation NZ

November 11, 2015
Tweet

Transcript

  1. 0 2 0 4 0 6 0 8 0 1

    2 0 1 4 0 1 6 0 1 8 0 2 0 0 E x e rc is e T o le ra n c e o n D o u b le t C h e m o th e ra p y D a y N u m b e r o f s te p -u p s in 5 m in s First experience of chemo effect Begin Docetaxel Cancer Diagnosis Begin Doublet Chemotherapy
  2. 0 5 0 1 0 0 1 5 0 2

    0 0 0 1 0 2 0 3 0 E x e rc is e T o le ra n c e o n D o c e ta x e l C h e m o th e ra p y D a y T im e e n d u rin g h ig h in te n s ity e x e rc is e (m in s ) Begin Targeted Therapy Begin Docetaxel
  3. January 2014 – Biopsy tests positive for ALK mutation February

    2014 – Begin targeted therapy, ALK inhibitor
  4. 0 1 0 2 0 3 0 4 0 5

    0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 0 2 0 4 0 6 0 8 0 M a x im u m E x e rc is e L o a d o n T a rg e te d T h e ra p y D a y T o ta l T im e (J o g & W a lk ) (m in ) Begin Targeted Therapy
  5. 0 1 0 2 0 3 0 4 0 5

    0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 0 2 0 4 0 6 0 8 0 E x e rc is e T o le r a n c e o n T a rg e tte d T h e ra p y D a y L o n g e s t c o n tin u o u s jo g (m in ) Begin Targeted Therapy
  6. 0 1 0 2 0 3 0 4 0 5

    0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 0 2 0 4 0 6 0 8 0 E x e rc is e T o le r a n c e o n T a rg e tte d T h e ra p y D a y L o n g e s t c o n tin u o u s jo g (m in ) Begin Targeted Therapy
  7. 0 1 0 2 0 3 0 4 0 5

    0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 0 2 0 4 0 6 0 8 0 E x e rc is e T o le r a n c e o n T a rg e tte d T h e ra p y D a y L o n g e s t c o n tin u o u s jo g (m in ) Begin Targeted Therapy
  8. 0 1 0 2 0 3 0 4 0 5

    0 6 0 7 0 8 0 9 0 1 0 0 1 1 0 0 2 0 4 0 6 0 8 0 D a y M in u te s T otal T im e L o n g e st R u n Begin Targeted Therapy
  9. 5-year survival rates have improved markedly for many cancers in

    recent decades – but not for lung cancer
  10. WHAT I WOULD LIKE TO SEE – POLICIES AIMED AT:

    1. Minimizing risk 2. Maximizing early detection 3. Wider availability of optimal treatments 4. Investment in the development of new treatments  X X X